Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100281 | 0.85 | EPHX2 (0.72) | EPHX2LMNAMEN1KMT2ACNR2 | |
| SCHEMBL4037025 | 0.84 | EPHX2 (1.00) | EPHX2LMNAMEN1KMT2ACNR2 | |
| SCHEMBL4099352 | 0.84 | EPHX2 (0.70) | EPHX2LMNAMEN1KMT2ACNR2 | |
| SCHEMBL12884438 | 0.76 | EPHX2 (0.63) | EPHX2LMNAMEN1KMT2ACNR2 | |
| SCHEMBL4015835 | 0.76 | EPHX2 (0.76) | EPHX2EPHX1 | |
| SCHEMBL12443646 | 0.76 | LMNA (0.71) | EPHX2LMNAMEN1KMT2ACNR2 | |
| SCHEMBL12488450 | 0.75 | EPHX2 (0.58) | EPHX2LMNAMEN1KMT2ACNR2 | |
| SCHEMBL26499136 | 0.73 | CACNA1H (0.81) | EPHX2LMNAKMT2AALDH1A1KDM4E | |
| SCHEMBL10016587 | 0.72 | USP2 (0.55) | EPHX2LMNACNR2HTTALDH1A1 | |
| SCHEMBL4106627 | 0.71 | EPHX2 (0.57) | EPHX2LMNAMEN1KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | EPHX2 3669/4885LMNA 2739/4885MEN1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.